Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Lipidor AB
Deal Size : Undisclosed
Deal Type : Agreement
Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate
Details : Lipidor AB has penned an agreement with Cadila Pharmaceuticals to conduct a Phase III study for Lipidor’s drug candidate AKP-02. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor’s spr...
Product Name : AKP02
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 07, 2020
Lead Product(s) : Calcipotriol,Betamethasone
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Lipidor AB
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SCD-044
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : $145.0 million
Deal Type : Licensing Agreement
SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases
Details : Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 cli...
Product Name : SCD-044
Product Type : Other Small Molecule
Upfront Cash : $20.0 million
May 29, 2020
Lead Product(s) : SCD-044
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : $145.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AUR101
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurigene announces dose administration in first patient study for phase II study of psoriasis
Details : The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.
Product Name : AUR101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : AUR101
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable